An executive's departure at a sensitive time has investors nervous.
Which purveyor of high-margin, nonintoxicating cannabis products will earn the largest share of this growing market?
Here's what needs to happen if these marijuana stocks are going to come bouncing back.
Here's why you'll want to keep both eyes on these market leaders.
Here's how companies from three different corners of the industry squeezed out a profit in the second quarter.
It's going to take more than a couple of embarassing revelations to stop this train.
During the second quarter, the company upgraded the safety net under its lead candidate.
For a few companies, the second half of 2019 will probably work out better than investors dared hope for earlier this year.
The Senhance Surgical System's launch isn't progressing nearly as well as investors had hoped.
Investors are cheering second-quarter results that were better than expected, and an improved outlook for the year.
A confluence of bad news has sunk the stock to a 20-year low.
These industry giants could make big moves after this year's World Conference on Lung Cancer.
Find out how concerned Vertex investors should be about a potential new cystic fibrosis treatment.
Sales of Hetlioz and Fanapt are exceeding expectations.
Amgen's rookie lineup continued to offset losses from the oldest members of its roster during the second quarter.
At first glance, an acquisition announcement looked like the wrong deal.
It looks like 2019's going to be much better than expected for these giants operating in different corners of the healthcare sector.
This pair of healthcare businesses made their public debut in June, but they're already making a big impression.
This hospital operator's investors are dreaming about a future spinoff.
This company is making drug development look much easier than it really is.